<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0034-7523</journal-id>
<journal-title><![CDATA[Revista Cubana de Medicina]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Cuban de Med]]></abbrev-journal-title>
<issn>0034-7523</issn>
<publisher>
<publisher-name><![CDATA[Centro Nacional de Información de Ciencias MédicasEditorial Ciencias Médicas]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0034-75232025000100024</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Utilidad de la tirzepatida para el tratamiento de la diabetes mellitus y la obesidad]]></article-title>
<article-title xml:lang="en"><![CDATA[Usefulness of Tirzepatide for the Treatment of Diabetes Mellitus and Obesity]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Rodríguez]]></surname>
<given-names><![CDATA[José]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Endocrinología  ]]></institution>
<addr-line><![CDATA[ La Habana]]></addr-line>
<country>Cuba</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>64</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S0034-75232025000100024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S0034-75232025000100024&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S0034-75232025000100024&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción:  La obesidad y la diabetes mellitus tipo 2 son enfermedades frecuentes que afectan la salud y la calidad de vida. Conocer la tirzepatida como un nuevo fármaco que se indica para el tratamiento de ambas dolencias y este puede mejorar la salud de los afectados.  Objetivo:  Describir la utilidad de la tirzepatida para el tratamiento de la diabetes mellitus y la obesidad.  Métodos:  Se realizó una revisión bibliográfica y se utilizaron como palabras clave: tirzepatida; agonista del receptor del péptido similar al glucagón tipo 1; obesidad; diabetes mellitus tipo 2; diabesidad. Para la búsqueda de información se emplearon las bases de datos Google Académico, SciELO y PubMed. Se incluyeron estudios de revisión, investigación y páginas Web, que tenían menos de 5 años de publicación en idioma español, portugués o inglés. Cumplieron con los criterios de selección 41 artículos que abordaran la relación de la tirzepatida con la diabetes mellitus y la obesidad.  Conclusiones: La tirzepatida es útil para el tratamiento de los pacientes con obesidad y diabetes mellitus, puede proporcionar una alternativa segura y eficaz. Esto se debe a que los mecanismos multifacéticos actúan y facilitan la pérdida de peso, mejora el control glucémico y lipídico, así como la grasa visceral, y a su vez contribuye a la disminución del riesgo cardiovascular.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT  Introduction:  Obesity and type 2 diabetes mellitus are common diseases that affect health and quality of life. To learn about tirzepatide as a new drug that is indicated for the treatment of both conditions and that can improve the health of those affected.  Objective:  To describe the usefulness of tirzepatide for the treatment of diabetes mellitus and obesity.  Methods:  A bibliographic review was carried out and the following keywords were used: tirzepatide; glucagon-like peptide type 1 receptor agonist; obesity; type 2 diabetes mellitus; diabesity. Google Scholar, SciELO and PubMed databases were used to search for information. Review studies, research studies and Web pages that were published less than 5 years ago in Spanish, Portuguese or English were included. Forty-one articles that addressed the relationship among tirzepatide and diabetes mellitus and obesity met the selection criteria.  Conclusions:  Tirzepatide is useful for the treatment of patients with obesity and diabetes mellitus, and may provide a safe and effective alternative. This is because multifaceted mechanisms act and facilitate weight loss, improve glycemic and lipid control, as well as visceral fat, and in turn contribute to the reduction of cardiovascular risk.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[tirzepatida]]></kwd>
<kwd lng="es"><![CDATA[agonista del receptor del péptido similar al glucagón tipo 1]]></kwd>
<kwd lng="es"><![CDATA[obesidad]]></kwd>
<kwd lng="es"><![CDATA[diabetes mellitus tipo 2]]></kwd>
<kwd lng="es"><![CDATA[diabesidad]]></kwd>
<kwd lng="en"><![CDATA[tirzepatide]]></kwd>
<kwd lng="en"><![CDATA[glucagon-like peptide type 1 receptor agonist]]></kwd>
<kwd lng="en"><![CDATA[obesity]]></kwd>
<kwd lng="en"><![CDATA[type 2 diabetes mellitus]]></kwd>
<kwd lng="en"><![CDATA[diabesity]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<collab>Organización Panamericana de la Salud (OPS)</collab>
<source><![CDATA[Diabetes. Perfiles de países - Carga de enfermedad diabetes 2023]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<collab>Federación Internacional de Diabetes</collab>
<source><![CDATA[Datos y cifras]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>Organización Mundial de la Salud (OMS)</collab>
<source><![CDATA[Obesidad y sobrepeso. Datos y cifras]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Calderín]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Generalidades sobre las consecuencias del sobrepeso corporal y de la obesidad en la salud]]></article-title>
<source><![CDATA[Rev Cubana Endocrinol]]></source>
<year>2020</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pujol]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[11 consecuencias de la obesidad para la salud de las personas]]></source>
<year>2021</year>
<publisher-name><![CDATA[UCOM]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guzmán]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Rubio]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brito]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Nuevas incretinas poliagonistas en la DM2. Tratamientos. Diabetes]]></source>
<year>2024</year>
<volume>85</volume>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>World Obesity Federation</collab>
<source><![CDATA[World Obesity Atlas 2023]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De la Vega]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Morquecho]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Isidro]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Ramírez]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Análisis del concepto "Diabesidad"]]></article-title>
<source><![CDATA[Index Enferm]]></source>
<year>2022</year>
<volume>31</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>289-93</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nauck]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Müller]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incretin hormones and type 2 diabetes]]></article-title>
<source><![CDATA[Diabetología]]></source>
<year>2023</year>
<volume>66</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1780-95</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mejía]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos de los agonistas del receptor de péptido similar al glucagón tipo 1 como tratamiento en pacientes con obesidad y diabetes mellitus tipo 2]]></article-title>
<source><![CDATA[Rev Haban Cienc Méd]]></source>
<year>2022</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Górriz]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Soler]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Puchades]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[D&#8217;Marco]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[GLP-1 receptor agonists and diabetic kidney disease: A call of attention to nephrologists]]></article-title>
<source><![CDATA[J Clin Med]]></source>
<year>2020</year>
<volume>9</volume>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Profundizando en la eficacia y seguridad de un nuevo antidiabético: la semaglutida subcutánea]]></article-title>
<source><![CDATA[Hoja de Evaluación de Medicamentos de Castilla-La Mancha]]></source>
<year>2021</year>
<volume>XXII</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<source><![CDATA[U.S. Food and Drug Administration (FDA). FDA Approves New Medication for Chronic Weight Management. FDA News Release]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="">
<source><![CDATA[Tirzepatida (MounjaroTM), de Lilly, consigue una pérdida media total de peso del 26 % en personas con obesidad y sobrepeso y, al menos, una comorbilidad, tras 88 semanas. SURMOUNT-4. 12 de diciembre de 2023:1-4]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<collab>European Medicines Agency (EMA)</collab>
<source><![CDATA[Información general sobre Mounjaro y sobre los motivos por los que se autoriza su uso en la UE]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cases]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2: Una aproximación para el nefrólogo]]></article-title>
<source><![CDATA[Nefrología]]></source>
<year>2023</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>399-412</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Función de la dulaglutida, una opción terapéutica en las personas con diabesidad]]></article-title>
<source><![CDATA[Revista Cubana de Endocrinología]]></source>
<year>2023</year>
<volume>33</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>Agencia española de medicamentos y productos sanitarios</collab>
<source><![CDATA[Ficha técnica Mounjaro 12,5 mg solución inyectable en pluma precargada]]></source>
<year>2023</year>
<publisher-name><![CDATA[CIMA]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hernández]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[La semaglutida en el tratamiento de las personas con diabesidad]]></article-title>
<source><![CDATA[Rev. Cuban de Med]]></source>
<year>2023</year>
<volume>62</volume>
<numero>1</numero>
<issue>1</issue>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coskun]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sloop]]></surname>
<given-names><![CDATA[KW]]></given-names>
</name>
<name>
<surname><![CDATA[Loghin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alsina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Urva]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bokvist]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept]]></article-title>
<source><![CDATA[Mol Metab]]></source>
<year>2018</year>
<volume>18</volume>
<page-range>3-14</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Nauck]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Van]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kutner]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Cui]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Benson]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2018</year>
<volume>392</volume>
<numero>10160</numero>
<issue>10160</issue>
<page-range>2180-93</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>Eli Lilly and Company</collab>
<source><![CDATA[FDA Approves Lilly's Zepbound&#8482; (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems]]></source>
<year>2023</year>
<publisher-name><![CDATA[Eli Lilly]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Forzano]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Varzideh]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Avvisato]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jankauskas]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Mone]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Santulli]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide: A systematic update]]></article-title>
<source><![CDATA[International Journal of Molecular Sciences]]></source>
<year>2023</year>
<volume>23</volume>
<numero>23</numero>
<issue>23</issue>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garvey]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Jastreboff]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[le Roux]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Aizenberg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2023</year>
<volume>402</volume>
<numero>10402</numero>
<issue>10402</issue>
<page-range>613-26</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="book">
<collab>Agencia española de medicamentos y productos sanitarios</collab>
<source><![CDATA[Informe de Posicionamiento Terapéutico de tirzepatida (Mounjaro®) en diabetes mellitus tipo 2]]></source>
<year>2023</year>
<publisher-name><![CDATA[Ministerio de Sanidad]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="">
<collab>Vademecum</collab>
<source><![CDATA[Mounjarro 5 mg solución inyectable en pluma precargada. Ficha técnica. Vidal Vademecum Spain]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wysham]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Frías]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Kaneko]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>398</volume>
<numero>10295</numero>
<issue>10295</issue>
<page-range>143-55</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Frías]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[FC]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bergman]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SURPASS-2 Investigators. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2021</year>
<volume>385</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>503-15</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ludvik]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Giorgino]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Jódar]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>398</volume>
<numero>10300</numero>
<issue>10300</issue>
<page-range>583-98</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Del Prato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Pavo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Weerakkody]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Doupis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2021</year>
<volume>398</volume>
<numero>10313</numero>
<issue>10313</issue>
<page-range>1811-24</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dahl]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Onishi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Norwood]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Huh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of subcutaneous tirzepatide vs. placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2022</year>
<volume>327</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>534-45</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rosenstock]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Frías]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Rodbard]]></surname>
<given-names><![CDATA[HW]]></given-names>
</name>
<name>
<surname><![CDATA[Tofé]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sears]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Huh]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide vs insulin lispro added to basal insulin in type 2 diabetes: the SURPASS-6 randomized clinical trial]]></article-title>
<source><![CDATA[Jama]]></source>
<year>2023</year>
<volume>330</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1631-40</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gastaldelli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cusi]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Bray]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwers]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial]]></article-title>
<source><![CDATA[Lancet Diabetes Endocrinol]]></source>
<year>2022</year>
<volume>10</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>393-406</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicholls]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bhatt]]></surname>
<given-names><![CDATA[DL]]></given-names>
</name>
<name>
<surname><![CDATA[Buse]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Del Prato]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Kahn]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Lincoff]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS&#8208;CVOT design and baseline characteristics]]></article-title>
<source><![CDATA[American Heart Journal]]></source>
<year>2024</year>
<volume>267</volume>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jastreboff]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Aronne]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[NN]]></given-names>
</name>
<name>
<surname><![CDATA[Wharton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Connery]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Alves]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide once weekly for the treatment of obesity]]></article-title>
<source><![CDATA[New England Journal of Medicine]]></source>
<year>2022</year>
<volume>387</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>205-16</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garvey]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Frias]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Jastreboff]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[le Roux]]></surname>
<given-names><![CDATA[CW]]></given-names>
</name>
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Aizenberg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2023</year>
<volume>402</volume>
<numero>10402</numero>
<issue>10402</issue>
<page-range>613-26</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[XH]]></given-names>
</name>
<name>
<surname><![CDATA[Chew]]></surname>
<given-names><![CDATA[HSJ]]></given-names>
</name>
<name>
<surname><![CDATA[Goh]]></surname>
<given-names><![CDATA[RSJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Anand]]></surname>
<given-names><![CDATA[VV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of tirzepatide for treatment of overweight or obesity. A systematic review and meta-analysis]]></article-title>
<source><![CDATA[Int J Obes (Lond)]]></source>
<year>2023</year>
<volume>47</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>677-85</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aronne]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sattar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Horn]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Bays]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Wharton]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[WY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2024</year>
<volume>331</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>38-48</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gotés]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[SURMOUNT-2: análisis de tirzepatida en personas con obesidad y diabetes. Noticias y Perspectivas]]></source>
<year>2023</year>
<publisher-name><![CDATA[Medscape]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hankosky]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Neff]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Kan]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ahmad]]></surname>
<given-names><![CDATA[NN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc análisis]]></article-title>
<source><![CDATA[Diabetes, Obesity and Metabolism]]></source>
<year>2023</year>
<volume>26</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>319-28</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sinha]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Papamargaritis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sargeant]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Davies]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management]]></article-title>
<source><![CDATA[J Obes Metab Syndr]]></source>
<year>2023</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>25-45</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
